|
Market Closed -
Nasdaq
01:30:00 31/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 30.55 USD | -17.94% |
|
-17.43% | +12.23% |
| 30/10 | Agios Pharmaceuticals Shares Fall on FDA Review Extension | DJ |
| 30/10 | Agios Pharmaceuticals' PDUFA Goal Date for Sickle Cell Disease Treatment Mitapivat Extended by FDA; Shares Fall Pre-Bell | MT |
| Market Cap | 182.39Cr 163.35Cr 150.25Cr 136.14Cr 254.48Cr 17TCr 259.25Cr 1.79TCr 719.29Cr 9.11TCr 684.49Cr 669.93Cr 29TCr | P/E 2026 * |
-5.3x | P/E 2027 * | -8.16x |
|---|---|---|---|---|---|
| Enterprise Value | 169.05Cr 151.4Cr 139.26Cr 126.18Cr 235.87Cr 16TCr 240.28Cr 1.66TCr 666.67Cr 8.44TCr 634.42Cr 620.93Cr 27TCr | EV / Sales 2026 * |
9.54x | EV / Sales 2027 * | 5.2x |
| Free-Float |
77.8% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| AGIO | Delayed | |
CBOE
| AGIO | Real-time | |
|
Tradegate
| 8AP | Real-time | |
|
Boerse Muenchen
| 8AP | Real-time | |
|
Deutsche Boerse AG
| 8AP | Delayed | |
|
Börse Stuttgart
| 8AP | Delayed | |
|
Berne S.E.
| 8AP | End-of-day quote |
Last Transcript: Agios Pharmaceuticals, Inc.
| 1 day | -17.94% | ||
| 1 week | -17.43% | ||
| Current month | -8.12% | ||
| 1 month | -8.12% | ||
| 3 months | -6.72% | ||
| 6 months | +9.11% | ||
| Current year | +12.23% |
| 1 week | 29.8 |  | 38.69 |
| 1 month | 29.67 | | 38.69 |
| Current year | 24.29 | | 44.09 |
| 1 year | 22.24 | | 46 |
| 3 years | 20.4 | | 62.58 |
| 5 years | 16.75 | | 62.58 |
| 10 years | 16.75 | | 99.82 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 57 | 08/08/2022 |
Cecilia Jones
DFI | Director of Finance/CFO | 51 | 26/09/2022 |
Sarah Gheuens
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/09/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 09/12/2014 | |
May Kin Ho
BRD | Director/Board Member | 73 | 23/06/2015 |
David Scadden
BRD | Director/Board Member | 73 | 27/05/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 04/08/26 | Sell | Chief Technology Officer | -30,000 | 0.0504% | ||
| 08/07/26 | Free | Director | 2,894 | 0.0049% | ||
| 01/07/26 | Exercice | Chief Technology Officer | 20,757 | 0.0349% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.94% | -17.43% | -29.25% | +49.83% | 182.39Cr | |
| -0.62% | -1.87% | +46.31% | +56.99% | 6.38TCr | |
| +0.35% | +3.20% | +14.92% | +84.55% | 5.64TCr | |
| +0.53% | +1.96% | +15.37% | +106.81% | 5.46TCr | |
| -2.81% | -4.31% | +23.50% | +50.90% | 4.41TCr | |
| -0.33% | -1.93% | +20.15% | +98.45% | 4.21TCr | |
| +0.55% | +2.31% | +224.97% | +942.56% | 4.1TCr | |
| +3.27% | +47.96% | +112.67% | +96.48% | 3.49TCr | |
| +1.22% | -1.44% | +14.89% | +47.15% | 3.28TCr | |
| +0.89% | +20.55% | -42.03% | +373.03% | 2.47TCr | |
| Average | -1.49% | +5.04% | +40.15% | +190.67% | 3.96TCr | |
| Weighted average by Cap. | +0.09% | +5.34% | +48.14% | +185.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18Cr 16Cr 15Cr 13Cr 25Cr 1.68TCr 25Cr 174.05Cr 70Cr 884.89Cr 66Cr 65Cr 2.79TCr | 35Cr 31Cr 29Cr 26Cr 48Cr 3.3TCr 49Cr 341.31Cr 137.01Cr 1.74TCr 130.39Cr 127.61Cr 5.47TCr |
| Net income | -34Cr -31Cr -28Cr -26Cr -48Cr -3.26TCr -49Cr -337.24Cr -135.38Cr -1.71TCr -128.83Cr -126.09Cr -5.41TCr | -23Cr -21Cr -19Cr -17Cr -33Cr -2.21TCr -33Cr -229.08Cr -92Cr -1.16TCr -88Cr -86Cr -3.67TCr |
| Net Debt | -13Cr -12Cr -11Cr -9.96Cr -19Cr -1.27TCr -19Cr -131.08Cr -53Cr -666.42Cr -50Cr -49Cr -2.1TCr | -1.83Cr -1.64Cr -1.51Cr -1.36Cr -2.55Cr -173.48Cr -2.6Cr -18Cr -7.21Cr -91Cr -6.86Cr -6.71Cr -287.79Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | $30.55 | -17.94% | 30,94,763 |
| 29/26/29 | $37.23 | -2.33% | 9,84,412 |
| 28/26/28 | $38.12 | +0.24% | 14,01,038 |
| 27/26/27 | $38.03 | +3.20% | 7,39,087 |
| 26/26/26 | $36.85 | -0.41% | 8,38,543 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AGIO Stock
Select your edition
All financial news and data tailored to specific country editions
